Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study

Hwi-Seung KIM; Taekwan YOON; Chang-Hee JUNG; Joong-Yeol PARK; Woo-Je LEE.
Diabetes & Metabolism Journal ; : 658-662, 2022.
Artículo en Inglés | WPRIM | ID: wpr-937421

Documentos relacionados

  1. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.
  2. [The treatment of diabetes mellitus: myths and evidence].
  3. [A 20-year prospective follow-up study to evaluate the development of retinopathy and nephropathy after the onset of type 1 diabetes mellitus: Contribution of glycemic control and metabolic memory].
  4. [Diabetes mellitus: endothelial dysfunction and changes in hemostasis].
  5. [Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review].
  6. [Laboratory investigations in clinical diabetic practice].
  7. [Schizophrenia and diabetes mellitus: not an improbable combination].
  8. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
  9. [Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?].
  10. [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen].